Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangzhuo Qinggan is a multi-component Traditional Chinese Medicine (TCM) herbal prescription developed for the treatment of essential hypertension and metabolic syndrome, specifically targeting patients diagnosed with the Hepatogastric Damp-heat syndrome. The formula is designed to address the cluster of metabolic abnormalities including high blood pressure, dyslipidemia, and impaired glucose tolerance. Its therapeutic approach focuses on "clearing liver fire" and "resolving turbid dampness," which are central concepts in TCM pathology for metabolic disorders. Clinical investigation has focused on its efficacy as both a standalone treatment and a complementary therapy compared to standard western medications like irbesartan, evaluating its impact on blood pressure reduction and the improvement of metabolic biomarkers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiangzhuo Qinggan.